Matthew Paul Greving

Title: The Innovations of Matthew Paul Greving

Introduction

Matthew Paul Greving is a notable inventor based in San Diego, California. He has made significant contributions to the field of biotechnology, particularly in the development of engineered polypeptides and antibodies. With a total of eight patents to his name, Greving's work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Greving's latest patents include innovative engineered CD25 polypeptides and their applications. These engineered polypeptides incorporate spatially-associated topological constraints, with at least one constraint derived from a CD25 reference target. The patents also describe methods for selecting these engineered polypeptides, which can be utilized as positive or negative selection molecules in screening libraries of binding molecules, such as antibodies. Additionally, Greving has developed CD25 antibodies that specifically bind to CD25, with therapeutic applications for treating cancer and autoimmune diseases. These antibodies may disrupt the trimerization of the IL-2 receptor's beta, gamma, and alpha chains, and exhibit higher binding affinity at lower pH levels.

Career Highlights

Throughout his career, Greving has worked with various companies, including Ibio Limited. His innovative work has led to advancements in the understanding and treatment of diseases, showcasing his expertise in biotechnology and molecular engineering.

Collaborations

Greving has collaborated with notable individuals in his field, including Trent Russell Northen and Kevin Eduard Hauser. These collaborations have likely contributed to the success and development of his patented technologies.

Conclusion

Matthew Paul Greving is a distinguished inventor whose work in engineered polypeptides and antibodies holds promise for future therapeutic applications. His contributions to biotechnology continue to pave the way for advancements in medical treatments.